Welcome | Sign In
CRMBuyer.com
Business

European Union Gives Nod to Oracle-PeopleSoft Merger

Print Version
E-Mail Article
Reprints
European Union Gives Nod to Oracle-PeopleSoft Merger

While the EU ruling -- combined with the U.S. Department of Justice decision to accept a court ruling that the merger would not violate antitrust laws -- removes the primary obstacle to the deal's completion, PeopleSoft's poison pill remains a barrier.


eMarketer Whitepaper: Optimizing the E-Commerce Experience
From the Web to the Contact Center, are you prepared to proactively engage and keep your savvy customers? Read how e-commerce leaders are optimizing their sites with ratings, reviews, live help, Web analytics, mobile and more.

The European Commission, the regulatory body of the European Union, today removed the final anti-trust barrier to Oracle's (Nasdaq: ORCL) takeover of PeopleSoft.

Not only did the European Commission meeting in Brussels, Belgium, end its yearlong consideration of the merger in Oracle's favor, it did so without stipulations.

"The EU evaluation was whether the combination of Oracle and PeopleSoft would hinder competition," said Jeff Comport, an analyst with Gartner (NYSE: IT), in a conversation with CRM Buyer this morning. The commission found that the newly joined Oracle-PeopleSoft and the German firm SAP (NYSE: SAP) would not form a duopoly. "There still would be enough competition," Comport said.

Enough Competition

"The European Commission would have the authority to deny permission unless certain conditions were met, such as spinning off a part of the company [or] spinning off a CRM product," Comport said. But it found that challengers remain formidable enough, even in the face of a merged Oracle and PeopleSoft, that the commission saw no need for restrictions, he said.

While this decision -- combined with the U.S. Department of Justice decision in the summer to accept a court ruling that the merger would not violate antitrust laws -- removes the primary obstacle to the deal's Increase Customer Sales with Email Marketing -- Free Trial from VerticalResponse completion, "the poison pill is a real barrier," Comport said.

That barrier might "be overcome with price, but it's still relevant." Poison Pill Remains PeopleSoft's "flip-in" poison pill would allow its current shareholders to double their shares at a discount, effectively doubling Oracle's cost to acquire the business.

At this point, PeopleSoft's poison pill will determine whether the takeover happens, how soon it happens and at what price, Comport said. In the meantime, he's not looking into his crystal ball when advising clients.

"Oracle's pursuing and PeopleSoft is still actively resisting. We're still advising clients to think about both possibilities" -- that the companies merge or remain separate -- "when considering doing business with one," he said.


Print Version E-Mail Article Reprints More by Kelly Shermach


More by Kelly Shermach

Does SaaS Meet the Customization Challenge?
April 17, 2007
SaaS market leaders have improved their customization options to meet most enterprise needs, says Michael Greenberg , vice president of marketing at Loyalty Lab. "Salesforce.com leads the way with their Apex platform providing a dizzying array of options to incorporate SaaS into any enterprise environment."
Getting Physical With Online Shopping
April 14, 2007
"Because each customer has a different buying style, unique selection criteria, personal motivations and shopping approach, retailers must deliver a more dynamic experience to better accommodate customer preferences," notes Errol Denger, senior strategist for WebSphere commerce at IBM.
Accenture Partner Garret Wu: Health Info Prototype Is One Small Step
April 11, 2007
"Accenture's prototype introduces both common language and data standards, and integrates information across the entire healthcare system. It enables a single view of a patient's medical information. This helps provide better patient care, more consistent care and supports the secondary use of data," said Garret Wu, a partner at Accenture Health & Life Sciences.
Don't miss a story -- sign up for our FREE e-mail newsletters and view the latest headlines at a glance.
Tech News Flash [ View Sample ]
E-Commerce Minute [ View Sample ]
ECT News Network Weekly Newsletter [ View Sample ]
Shortcuts
ECT News Network Information
Reader Services
Corporate
ECT News Network